-
stimulating factor (r-metHuG-CSF). In 2015, Sandoz's filgrastim-sndz (trade name
Zarxio),
obtained the
approval of the U.S. Food and Drug
Administration (FDA) as...
-
biologic under the FD&C Act. On
March 6, 2015,
Zarxio obtained the
first approval of FDA. Sandoz's
Zarxio is
biosimilar to Amgen's
Neupogen (filgrastim)...
- 2013.
Retrieved 2019-06-28.
Medscape (23
April 2019). "Neupogen, Granix,
Zarxio,
Nivestym (filgrastim, tbo-filgrastim, filgrastim-sndz, filgrastim-aafi...
-
biosimilar was only
approved in the US by the FDA in 2015:
Zarxio, made by Sandoz.
Zarxio is a
biosimilar of the
cancer drug Neupogen,
which boosts the...
